1. What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the full 43-amino-acid protein made by the body. TB-500 is just a short, synthetic 7-amino-acid fragment of it.
2. Has TB-500 been tested in human clinical trials?
No, TB-500 has zero human clinical trials. All the human data you see cited online actually comes from studies on the full-length protein.
3. Why do vendors conflate TB-500 with Thymosin Beta-4?
They use the full protein’s human data to market the fragment because both share the same localized wound-healing domain.
4. What healing mechanisms is TB-500 missing?
It lacks the sections needed for deep signaling, meaning it likely misses out on the heart repair and anti-scarring benefits of the full protein.
5. What is the Rahaman 2024 metabolite finding?
A 2024 study showed TB-500 quickly breaks down into a smaller piece (Ac-LKKTE), meaning that metabolite might be doing all the actual healing work.
6. Why do pharma companies only develop full-length Thymosin Beta-4?
Because the full protein triggers a much wider range of systemic healing and cell survival pathways that the tiny fragment cannot replicate.
7. Is TB-500 completely inactive?
No. Philp et al. (2003) demonstrated wound-healing activity for the seven-amino-acid fragment itself. It simply has a narrower functional range.
8. Can I apply Tβ4 research directly to TB-500?
No. The mechanisms overlap in the actin-binding domain, but the full protein has functional domains the fragment lacks.
9. What is TB-500’s molecular weight?
889.0 Da. Full-length Tβ4 is approximately 4,921 Da, roughly six times heavier.
10. What are the future research directions for TB-500?
Human clinical trials, independent confirmation of the Rahaman 2024 finding, and determining which Tβ4 functions the fragment retains.
Conclusion
TB-500 and thymosin beta-4 are not the same thing. Understanding their differences is the first step toward a rational assessment of TB-500.